Thursday , May 25 2017
Home / 2016 / September

Monthly Archives: September 2016

Ambry Genetics Launches Comprehensive Multi-Gene Test for Hereditary Prostate Cancer

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics (Ambry) today announces that it has launched ProstateNext, a new 14-gene panel for hereditary prostate cancer. Ambry will feature it at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference taking place September 28-October 1 in Seattle, WA. This also coincides with Prostate …

Read More »

FDA Approves Medtronic’s Automated Insulin Delivery Device for Type 1 Diabetes

The U.S. Food and Drug Administration today approved Medtronic’s MiniMed 670G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes. The human pancreas naturally supplies …

Read More »

Pairnomix Launches Screening Services Assisting Physicians to Identify Treatments Based on Rare Genetic Mutations

MAPLE GROVE, Minn., Sept. 28, 2016 /PRNewswire/ — Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today reported on the successful launch of its unique characterization and drug screening services that provide physicians with data on a patient’s …

Read More »

Daiichi Sankyo and Zymeworks Enter Immuno-Oncology Licensing and Collaboration Agreement

VANCOUVER, British Columbia & TOKYO & PARSIPPANY, N.J.–(BUSINESS WIRE)–Zymeworks Inc., a clinical-stage biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics including bi-specific antibodies and drug conjugates for the treatment of cancer, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a cross-licensing and …

Read More »

Summit Therapeutics’ DMD Drug Granted Rare Pediatric Disease Designation from the FDA

Oxford, UK, 27 September 2016 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today announces it has received Rare Pediatric Disease designation from the US Food and Drug Administration (‘FDA’) for ezutromid in …

Read More »

Boehringer Ingelheim to Co-Develop ViraTherapeutics’ Investigational Oncolytic Virus Therapy Platform

INGELHEIM, Germany & INNSBRUCK, Austria–(BUSINESS WIRE)–Boehringer Ingelheim and ViraTherapeutics today announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other therapies. ViraTherapeutics, a biopharmaceutical company specializing …

Read More »

Amgen’s Kyprolis Fails Key First-Line Multiple Myeloma Trial

THOUSAND OAKS, Calif., Sept. 27, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS® (carfilzomib), melphalan and prednisone (KMP) versus Velcade® (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma …

Read More »

Prime Therapeutics Research Finds Nearly Half of Members Discontinue Costly RA Drug After One Year

ST. PAUL, MINN. – Sept. 27, 2016 – Prime Therapeutics LLC (Prime), a pharmacy benefit manager serving over 22 million members nationally, analyzed members’ use of rheumatoid arthritis (RA) drug tofacitinib (Xeljanz®) to find patterns and adherence behaviors. While use of the drug had been low (one member per 100,000 …

Read More »

Kite Pharma’s CAR-T Therapy Demonstrates Positive Results in Lymphoma Study

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE) today announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 met the primary endpoint of objective response rate (ORR), p<0.0001, with ORR of 76 percent, …

Read More »

Breaking Down Restrictions

For many years, the standard plan for treating hepatitis C infections called for excluding active drug users. Experts at the 5th International Symposium on Hepatitis Care in Substance Users who recently met in Oslo, aim to revise what is considered standard care. New research was discussed at the symposium, specifically …

Read More »